Gunther Spohn1, Natalia Arenas-Ramirez2, Gregory Bouchaud2, Onur Boyman3. 1. Cytos Biotechnology, Schlieren, Switzerland. Electronic address: cri.gunther@bluewin.ch. 2. Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 3. Department of Immunology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Electronic address: onur.boyman@uzh.ch.
Abstract
BACKGROUND: Particular neutralizing mAbs to certain cytokines act as agonists in vivo through protection of the cytokine's active site and prolongation of its half-life. Although this principle might be useful for targeted immunotherapy, its role in the pathogenesis of inflammation and autoimmunity is unclear. OBJECTIVE: We sought to determine whether slight, structurally nonrelevant modifications of the prototypic proinflammatory cytokine IL-1β during an immune response could elicit polyclonal anti-IL-1β antibody responses that modulated IL-1β's in vivo activity. METHODS: We engineered 2 different IL-1β variants, thereby mimicking the process of cytokine modification occurring during inflammation, and conjugated them to virus-like particles, followed by immunization of mice. The resulting polyclonal anti-IL-1β antibody responses were assessed by using in vitro and in vivo assays, as well as 2 relevant (auto-) inflammatory murine models. RESULTS: Although antibody responses generated to one variant were potently inhibiting IL-1β, antibody responses induced by the other variant even potentiated the in vivo effects of IL-1β; the latter led to enhanced morbidity in 2 different IL-1β-mediated mouse models, including a model of inflammatory bowel disease and an inflammatory arthritis model. CONCLUSION: These data demonstrate that endogenous polyclonal anti-cytokine antibody responses can enhance the cytokine's activity in inflammatory and autoimmune diseases.
BACKGROUND: Particular neutralizing mAbs to certain cytokines act as agonists in vivo through protection of the cytokine's active site and prolongation of its half-life. Although this principle might be useful for targeted immunotherapy, its role in the pathogenesis of inflammation and autoimmunity is unclear. OBJECTIVE: We sought to determine whether slight, structurally nonrelevant modifications of the prototypic proinflammatory cytokine IL-1β during an immune response could elicit polyclonal anti-IL-1β antibody responses that modulated IL-1β's in vivo activity. METHODS: We engineered 2 different IL-1β variants, thereby mimicking the process of cytokine modification occurring during inflammation, and conjugated them to virus-like particles, followed by immunization of mice. The resulting polyclonal anti-IL-1β antibody responses were assessed by using in vitro and in vivo assays, as well as 2 relevant (auto-) inflammatory murine models. RESULTS: Although antibody responses generated to one variant were potently inhibiting IL-1β, antibody responses induced by the other variant even potentiated the in vivo effects of IL-1β; the latter led to enhanced morbidity in 2 different IL-1β-mediated mouse models, including a model of inflammatory bowel disease and an inflammatory arthritis model. CONCLUSION: These data demonstrate that endogenous polyclonal anti-cytokine antibody responses can enhance the cytokine's activity in inflammatory and autoimmune diseases.
Authors: Patrick Taeschler; Carlo Cervia; Yves Zurbuchen; Sara Hasler; Christian Pou; Ziyang Tan; Sarah Adamo; Miro E Raeber; Esther Bächli; Alain Rudiger; Melina Stüssi-Helbling; Lars C Huber; Petter Brodin; Jakob Nilsson; Elsbeth Probst-Müller; Onur Boyman Journal: Allergy Date: 2022-04-08 Impact factor: 14.710
Authors: Rebecca A Flaherty; Deborah L Donahue; Katelyn E Carothers; Jessica N Ross; Victoria A Ploplis; Francis J Castellino; Shaun W Lee Journal: Front Cell Infect Microbiol Date: 2018-07-03 Impact factor: 5.293
Authors: Jakob H von Stemann; Ole B Pedersen; Henrik Hjalgrim; Christian Erikstrup; Henrik Ullum; Lise W Thørner; Margit Ah Larsen; Kristoffer S Burgdorf; Erik Sørensen; Morten B Hansen; Sisse R Ostrowski Journal: J Clin Immunol Date: 2020-01-15 Impact factor: 8.317